Prendio and BioProcure Tap Industry Veteran Larry Birch as CEO

Two laboratory procurement platforms backed by Arsenal Growth are betting that consolidation — and a seasoned industry insider — can crack open a market that's remained stubbornly analog. Prendio and BioProcure announced Monday they've appointed Larry Birch — a 25-year life sciences technology veteran and former Thermo Fisher executive — as their joint CEO, signaling the platforms are operating as a unified entity even if they haven't formally merged on paper.

The appointment comes as life sciences organizations struggle with procurement processes that haven't meaningfully evolved since the 1990s. Researchers at biopharma companies and academic labs still navigate fragmented vendor catalogs, manual purchase orders, and compliance workflows that feel closer to fax machines than the cloud-native tools transforming every other corner of enterprise software.

Birch's mandate is straightforward: turn two adjacent platforms into a single procurement operating system for an industry that buys $200 billion worth of lab supplies, reagents, and equipment annually — but does so through systems that wouldn't pass muster at a mid-sized SaaS startup.

"Most life sciences organizations are still managing procurement with spreadsheets, email chains, and legacy ERP systems that weren't built for the complexity of lab operations," Birch said in the announcement. "We're creating infrastructure that should have existed a decade ago."

Prendio and BioProcure operate under the same private equity roof — Arsenal Growth, the growth-focused arm of Arsenal Capital Partners. Arsenal Growth acquired BioProcure in 2022 and Prendio shortly after, a buy-and-build strategy aimed at stitching together point solutions in a market where no dominant software player exists.

The thesis: laboratory procurement is ripe for the same platformization that happened in corporate travel (Concur), marketing spend (Coupa), and IT asset management (ServiceNow). But it hasn't happened yet because life sciences buyers have unique needs — regulatory traceability, lot number tracking, temperature-controlled logistics, compliance documentation — that generic procurement tools can't handle.

Prendio focuses on procurement software and vendor marketplace aggregation, pulling supplier catalogs into a single search and ordering interface. BioProcure layers on group purchasing power, negotiating bulk pricing for its member organizations the way GPOs operate in hospital systems.

Together, the platforms serve more than 200 life sciences organizations, including biopharma companies, contract research organizations, and academic research institutions. Neither company has disclosed revenue figures, but Arsenal's willingness to install a single CEO across both entities suggests the integration is further along than the press release language implies.

Birch joins from Thermo Fisher Scientific, the $200 billion lab equipment and consumables giant that dominates the supply side of the market Prendio and BioProcure are trying to digitize. He spent a decade there in senior leadership roles, most recently as Chief Commercial Officer for the company's Laboratory Products and Biopharma Services segment.

Before Thermo Fisher, Birch led software and data businesses at PerkinElmer and Bruker, giving him fluency in both the lab operations world and the recurring-revenue SaaS model that Arsenal is betting on. His experience scaling enterprise sales teams and navigating regulatory environments — FDA, GxP, ISO compliance — makes him a logical fit for platforms trying to sell into risk-averse life sciences procurement departments.

What he hasn't done is run a venture- or PE-backed software company through a growth-stage sprint. Thermo Fisher, PerkinElmer, and Bruker are all public, slow-moving incumbents. Prendio and BioProcure are in a different mode: land customers fast, prove unit economics, and build a moat before a larger player decides procurement software is worth entering.

Still, Birch's rolodex matters. Life sciences procurement is a relationship-heavy market. Knowing the VP of Operations at every top-20 biopharma company — and understanding how their buying committees think — is worth more than a decade of SaaS sales experience in a different vertical.

The laboratory supply and equipment market is enormous. According to Grand View Research, the global lab consumables market alone was valued at $196 billion in 2023 and is projected to grow at a 7.1% CAGR through 2030, driven by biopharma R&D expansion, clinical diagnostics growth, and increased government funding for life sciences research.

But the infrastructure layer — the software that manages how organizations buy, track, and comply with all those pipette tips, reagents, and centrifuges — is virtually nonexistent. Most life sciences companies still rely on a patchwork of tools: ERP systems built for manufacturing (SAP, Oracle), generic procurement platforms (Coupa, Ariba), homegrown spreadsheets, and email.

The problem is that lab procurement isn't like buying office supplies. You can't just plug into Amazon Business and call it done. Life sciences buyers need lot traceability for regulatory audits, cold chain logistics for temperature-sensitive materials, certificate of analysis tracking, and vendor qualification workflows that satisfy FDA inspectors.

Generic procurement platforms don't handle this well. ERP systems can be configured to do it, but the customization is expensive and brittle. That's the wedge Prendio and BioProcure are exploiting: build purpose-fit software for a market large enough to support a vertical SaaS player, but specific enough that Coupa and SAP won't bother.

The biggest risk isn't that Coupa or SAP Ariba suddenly develop life sciences expertise. It's that Thermo Fisher or a peer decides to vertically integrate and launch their own procurement platform. Thermo Fisher already operates an e-commerce marketplace. If they added procurement workflow software on top, they'd have distribution, supplier relationships, and customer trust baked in.

Arsenal Growth hasn't announced a formal merger, but appointing a single CEO is a clear signal. The two platforms are being run as one business, even if the legal entities remain separate.

Prendio's software handles the workflow layer: requisitioning, approvals, vendor catalog aggregation, order routing, and spend analytics. BioProcure adds the group purchasing organization (GPO) model on top, pooling buying power across member organizations to negotiate better pricing with suppliers.

In theory, that's a powerful combination. Software creates stickiness and data; the GPO model creates immediate ROI for customers ("join our platform and save 15% on lab consumables"). But integrating two separate codebases, sales teams, and customer success organizations is messy. Arsenal is betting Birch can do it without alienating existing customers or losing momentum.

The real test will be whether the combined platform can prove it's more than just a cost-savings play. If Prendio-BioProcure is just a GPO with better UX, that's a nice business but not a venture-scale outcome. If it becomes the system of record for lab procurement — the place where compliance data lives, where spend forecasting happens, where vendor performance gets tracked — that's a different story.

Arsenal hasn't disclosed the combined entity's valuation, revenue, or funding plans. Both platforms were acquired at undisclosed terms, and neither has raised institutional venture capital. That suggests Arsenal is funding growth through debt or its own balance sheet, which limits how aggressive they can be on customer acquisition but also means they're not burning cash to hit a venture-style growth curve.

Life sciences procurement software has a retention problem. Lab managers and procurement directors are skeptical of new tools because failed implementations are expensive — not just in dollars, but in researcher time and compliance risk. If Prendio or BioProcure customers churn during the integration, it'll signal that the platforms aren't sticky enough to survive organizational upheaval.

Birch's first 90 days will likely focus on customer reassurance. Expect announcement emails, webinars, and one-on-one calls with key accounts. The message will be: nothing breaks, everything gets better, and the product roadmap accelerates.

Arsenal's buy-and-build strategy makes sense if you believe that lab procurement software is a "land grab" market — where the winner isn't the company with the best technology, but the one that signs up the most customers before competitors wake up.

The firm has done this before. Arsenal Capital Partners has a long track record in specialty chemicals, industrial services, and healthcare, often rolling up fragmented markets into consolidated platforms and selling to strategics or taking them public. Arsenal Growth, the software-focused arm, launched in 2020 with the same playbook: find vertical SaaS markets that are underdigitized, buy smaller players, integrate them, and scale.

Prendio and BioProcure fit the pattern. Both were bootstrapped or lightly funded. Both had product-market fit in specific niches (Prendio in software, BioProcure in GPO services) but lacked the capital or expertise to scale nationally. Arsenal provided the capital, and now Birch provides the operational horsepower.

The bet is that life sciences procurement will follow the same trajectory as other vertical SaaS markets: a long period of fragmentation, followed by rapid consolidation once a credible platform emerges. If Prendio-BioProcure can be that platform, the exit is either a strategic acquisition (Thermo Fisher, Danaher, PerkinElmer) or a public offering in a few years.

One risk: life sciences organizations are conservative and risk-averse. They don't adopt new software quickly, and they don't switch platforms easily once they've implemented one. If a competitor (or an internal tool) is "good enough," the switching costs might be too high for Prendio-BioProcure to overcome, even if their product is objectively better.

Another risk: the market might stay fragmented. Biopharma companies, academic labs, and CROs have different needs. What works for a 50-person biotech in Cambridge won't work for a 10,000-person pharma giant in Basel. If the market requires too much customization, Prendio-BioProcure won't be able to sell a standardized platform — and the unit economics fall apart.

The press release is light on product specifics, but the roadmap likely includes a few obvious next moves based on where other vertical procurement platforms have gone.

First: deeper ERP integrations. Most life sciences companies run SAP, Oracle, or Workday for financials. If Prendio-BioProcure can't push purchase orders, invoices, and receiving data into those systems automatically, procurement teams won't adopt it. That means building and maintaining native integrations with a dozen ERP platforms — expensive, boring, and essential.

Second: supplier network effects. The more suppliers that list their catalogs on Prendio's marketplace, the more valuable the platform becomes to buyers. That means sales efforts aimed at vendors, not just customers — a two-sided marketplace strategy that requires different incentives and go-to-market motions.

Third: data products. Once Prendio-BioProcure has spend data from 200+ organizations, they can start selling benchmarking reports, price analytics, and supplier scorecards back to customers. That's a high-margin revenue stream that doesn't require selling more software seats.

None of this is proprietary or defensible on its own. The moat comes from execution speed and customer lock-in. If Prendio-BioProcure can ship these features faster than competitors and embed themselves deeply enough into customers' procurement workflows, they win. If they can't, someone else will.

Birch's ability to prioritize ruthlessly will matter. Early-stage CEOs often try to build everything at once. Birch has the benefit of experience — and the pressure of a PE owner that expects clear milestones.

Customer retention through the transition. If Arsenal and Birch can keep churn below 5% annualized during the integration, that's a strong signal. If churn spikes, it means the platforms weren't as sticky as Arsenal thought.

New customer wins in the top 50 biopharma. Prendio and BioProcure likely have strong traction in mid-market and emerging biopharma. The real test is whether Birch's relationships can land contracts at Pfizer, Novartis, or Roche. Those deals take 18+ months to close, but announcements in the next year would validate the thesis.

Product velocity. How fast does the combined engineering team ship new features? If the roadmap stalls because the teams are stuck integrating backends, that's a red flag. If they ship visible improvements every quarter, it shows Arsenal didn't just buy two companies and hope for synergies — they actually have a plan.

Competitive moves from incumbents. Thermo Fisher, VWR (owned by Avantor), or Danaher could all decide that procurement software is strategic. If one of them acquires a competitor or launches a comparable platform, Prendio-BioProcure's window narrows fast.

Fundraising or M&A activity. Arsenal Growth typically holds portfolio companies for 3-5 years. If Prendio-BioProcure raises a growth round from an outside investor (or if Arsenal sells a minority stake), that's a signal the company is performing and Arsenal is positioning for an exit. If there's radio silence, it might mean integration is harder than expected.

Prendio and BioProcure are part of a broader pattern. Over the last decade, vertical SaaS companies have systematically attacked every industry that still runs on spreadsheets and email: construction (Procore, Buildertrend), agriculture (Granular, FarmLogs), manufacturing (Plex, Tulip), logistics (project44, Fourkites).

Life sciences procurement is late to the party, but that might be an advantage. The playbook is proven. Find a large, fragmented market with high compliance requirements. Build purpose-fit software that generic tools can't replicate. Land customers through ROI (cost savings, time savings, risk reduction). Expand through product breadth and lock-in.

The question is whether Arsenal and Birch can execute it faster than competitors. Lab procurement software won't stay underinvested forever. Either Prendio-BioProcure becomes the category winner in the next 24 months, or someone else does.

For now, the bet is on Birch. He's got the relationships, the domain expertise, and the operational chops. What he doesn't have is unlimited time. Private equity doesn't wait.